Valneva SE
NASDAQ:VALNBiotechnology
Healthcare
$5.34 +0.19%
+$0.01 today
- Market cap
- $507.98M
- Beta
- 1.40
- P/E (TTM)
- -2.9
- EPS (TTM)
- -$0.80
52W Low $5.06High $12.25
Volume 0.00M
Average 0.09M
Income Statement
Follow revenue through to earnings.
Revenue
$174.66M
FY 2025 · Annual
+3.0% YoYOperating Income
-$81.63M
FY 2025 · Annual
Net Income
-$115.19M
FY 2025 · Annual
Income Statement
EUR
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 348.09M | 361.3M | 153.71M | 169.58M | 174.66M |
| Cost of Revenue | 187.92M | 324.44M | 100.88M | 98.54M | 107.14M |
| Gross Profit | 160.17M | 36.86M | 52.84M | 71.04M | 67.52M |
| Gross Margin | 46.0% | 10.2% | 34.4% | 41.9% | 38.7% |
| Research & Development | 173.28M | 104.92M | 59.89M | 74.14M | 85.3M |
| Selling, General & Admin | 71.25M | 57.58M | 96.55M | 95.11M | 74.68M |
| Operating Expenses | 221.56M | 150.31M | 134.92M | 57.71M | 149.15M |
| Depreciation & Amortization | 14.28M | 21.04M | 17.58M | 19.59M | 21.75M |
| EBITDA | (38.74M) | (104.73M) | (57.72M) | 32.08M | (50.47M) |
| EBITDA Margin | -11.1% | -29.0% | -37.6% | 18.9% | -28.9% |
| Operating Income | (61.39M) | (113.44M) | (82.09M) | 13.33M | (81.63M) |
| Operating Margin | -17.6% | -31.4% | -53.4% | 7.9% | -46.7% |
| Interest Income | 249K | 260K | 1.21M | 2.36M | 1.8M |
| Interest Expense | 16.96M | 19.05M | 23.33M | 23.98M | 41.9M |
| Other Income / Expenses | (8.59M) | (31.37M) | (16.54M) | (24.82M) | (32.49M) |
| Income Before Tax | (69.98M) | (144.82M) | (98.63M) | (11.49M) | (114.12M) |
| Pre-Tax Margin | -20.1% | -40.1% | -64.2% | -6.8% | -65.3% |
| Income Tax Expense | 3.45M | (1.54M) | 2.8M | 761K | 1.07M |
| Net Income | (73.43M) | (143.28M) | (101.43M) | (12.25M) | (115.19M) |
| Net Margin | -21.1% | -39.7% | -66.0% | -7.2% | -66.0% |
| EPS (Basic) | (1.50) | (2.48) | (1.46) | (0.17) | (1.32) |
| EPS (Diluted) | (1.50) | (2.48) | (1.46) | (0.17) | (1.32) |
| 48.81M | 57.74M | 69.47M | 70.26M | 84.09M | |
| 48.81M | 57.74M | 69.31M | 70.26M | 84.09M |
VALN Earnings Waterfall · TTM
NASDAQ:VALN · Revenue to Net Income
Key Ratios
EPS$-1.63
Gross Margin27.1%
Net Margin-95.9%
P/E Ratio-5.0
P/S Ratio16.7
Analysis
$156.3M of revenue converted into -$138.0M of net income for the selected period. Gross margin is 27.1% and net margin is -95.9%, showing how much revenue survives after costs and taxes. EPS is $-1.63, tying the income statement back to per-share earnings.
Competitors
Peer companies in the same sector
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 6-K | 6-K filing | Nov 13, 2026 | |
| 6-K | 6-K filing | Nov 6, 2026 | |
| 6-K | 6-K filing | Oct 15, 2026 | |
| 6-K | 6-K filing | Oct 8, 2026 | |
| 6-K | 6-K filing | Aug 14, 2026 |
How much revenue does VALN generate?
Valneva SE (VALN) reported $174.66M of revenue in fiscal 2025.
Is VALN profitable?
Valneva SE (VALN) reported -$115.19M of net income, with a net margin of -66.0%.
Continue the stock analysis
Jump to another research area for this company.